secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2026-08-06T20:29:52+00:00
Accession:  0001104659-26-092058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem Q2 net product revenue $25.1M; cash runway extended into H2 2027 via $75M Oberland deal
--------------------------------------------------------------------------------

- Net product revenue of $25.1M from AVMAPKI FAKZYNJA CO-PACK, up from $2.1M in Q2 2025.
- Total revenue $40.1M (incl. $15M COPIKTRA milestone); GAAP net loss $34.7M ($0.35/share).
- Cash, equivalents & investments $136.4M; proforma $201.4M after $50M Oberland closing and $15M milestone.
- First patients dosed in all three TARGET-D Phase 2 trials of VS-7375; updated data expected October 2026.
- Appointed Michael P. Bailey to Board of Directors; non-dilutive royalty financing with Oberland Capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/0001104659-26-092058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer